Biomea Fusion Outlines Diabetes, Obesity Pipeline at Conference

Company sees cash runway to Q1 2027, expects clinical milestones without additional financing

Mar. 13, 2026 at 7:28am

Got story updates? Submit your updates here. ›

Biomea Fusion NASDAQ: BMEA outlined its focus on diabetes and obesity at the Citizens Life Sciences Conference, highlighting two internally developed programs and a series of clinical milestones expected over the coming quarters. President Ramses Erdtmann said the company is funded through the first quarter of 2027 and expects to reach planned milestones without additional financing.

Why it matters

Biomea Fusion's pipeline targets key unmet needs in diabetes and obesity, two major public health challenges. The company's lead program, icovamenib, aims to address the underlying disease biology of diabetes by improving pancreatic beta-cell function, potentially delaying or preventing the need for insulin therapy. Its oral obesity program seeks to improve on current GLP-1-based therapies by enhancing patient experience and persistence.

The details

Biomea Fusion is pursuing a two-asset strategy, with icovamenib as its lead program, a potential first-in-class menin inhibitor for diabetes, and an oral GLP-1-related compound for obesity. Icovamenib is designed to improve beta-cell function and mass, addressing the root cause of diabetes rather than just managing hyperglycemia. Early clinical data showed reductions in HbA1c and increases in C-peptide, a marker of insulin production, that persisted after dosing stopped. The obesity program aims to develop a more patient-friendly GLP-1 therapy with improved bioavailability and pharmacokinetics.

  • Biomea Fusion expects to report data from two phase II diabetes studies in Q4 2026.
  • The company plans to present data from its type 1 diabetes study in Q2 2026 after the study is fully vetted.
  • Results from the phase I single-ascending-dose and multiple-ascending-dose study of the oral obesity program are expected by the end of Q2 2026.

The players

Biomea Fusion

A clinical-stage biopharmaceutical company focused on developing small molecule therapies for diabetes and obesity.

Ramses Erdtmann

President of Biomea Fusion.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.